Literature DB >> 11941933

Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.

Thomas Griga1, Burkard May, Okka Pfisterer, Klaus-Michael Müller, Frank Brasch.   

Abstract

BACKGROUND/AIMS: Significantly enhanced serum levels of VEGF (vascular endothelial growth factor) were found in patients with inflammatory bowel disease. Peripheral blood mononuclear cells have been identified as one of the origins of the circulating VEGF. The present investigation examines the localization of VEGF at the site of inflammation in colonic mucosa of patients with Crohn's disease and ulcerative colitis.
METHODOLOGY: Immunohistochemical localization of VEGF and immunostaining for leukocytes were performed in colonic mucosal biopsies of 41 patients with Crohn's disease, 26 patients with ulcerative colitis and normal mucosal specimens of 5 patients with irritable bowel syndrome. Measurement of immunohistochemical staining for VEGF and for leukocytes within the epithelium and the lamina propria was performed separately by area morphometry using a computerized cell analysis system.
RESULTS: In both patients with Crohn's disease and ulcerative colitis immunohistochemical staining for VEGF within the lamina propria of inflamed colonic mucosa was significantly higher compared with noninflamed mucosa (Crohn's disease: 4.26% vs. 0.07%, P < 0.001; ulcerative colitis: 3.68% vs. 0.32%, P = 0.001). There was a significant correlation between immunostaining for leukocytes and VEGF within the lamina propria in both patients with Crohn's disease (r = 0.73, P < 0.05)) and ulcerative colitis (r = 0.67, P < 0.05). In Crohn's disease immunostaining for VEGF within the epithelium was significantly higher in inflamed mucosa compared with noninflamed mucosa (9.85% vs. 0.63%, P < 0.001). In contrast, strong immunostaining for VEGF has been observed in the epithelium of noninflamed mucosa (7.60%, P < 0.003), as well as in inflamed mucosa of patients with active ulcerative colitis (9.68%, P < 0.002) compared with noninflamed mucosa of patients with inactive ulcerative colitis (1.39%).
CONCLUSIONS: The present data indicate, that the increased VEGF expression within the epithelium and the interstitial accumulation of VEGF-producing leukocytes in inflamed mucosa may play an important role in the inflammatory mechanisms of Crohn's disease and ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11941933

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  12 in total

Review 1.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

2.  Serum angiogenin in inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Costas Xidakis; Konstantinos Karmiris; Aekaterini Sfiridaki; Ermioni Kandidaki; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 3.  Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer.

Authors:  Linda A Feagins; Rhonda F Souza; Stuart J Spechler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-05       Impact factor: 46.802

4.  Vascular endothelial growth factor in inflammatory bowel disease.

Authors:  Andreas Kapsoritakis; Aekaterini Sfiridaki; Efstratios Maltezos; Kostantinos Simopoulos; Alexandra Giatromanolaki; Efthimios Sivridis; Michael I Koukourakis
Journal:  Int J Colorectal Dis       Date:  2003-05-22       Impact factor: 2.571

5.  Thalidomide for treatment of severe intestinal bleeding.

Authors:  J Bauditz; G Schachschal; S Wedel; H Lochs
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

6.  Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease.

Authors:  Canan Alkim; Berna Savas; Arzu Ensari; Huseyin Alkim; Ulku Dagli; Erkan Parlak; Aysel Ulker; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2008-11-26       Impact factor: 3.199

7.  Thrombospondin-1 and VEGF in inflammatory bowel disease.

Authors:  Canan Alkim; Damlanur Sakiz; Huseyin Alkim; Ayten Livaoglu; Tulin Kendir; Huseyin Demirsoy; Levent Erdem; Nihat Akbayir; Mehmet Sokmen
Journal:  Libyan J Med       Date:  2012-01-30       Impact factor: 1.657

8.  VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

Authors:  A H R Varey; E S Rennel; Y Qiu; H S Bevan; R M Perrin; S Raffy; A R Dixon; C Paraskeva; O Zaccheo; A B Hassan; S J Harper; D O Bates
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

9.  Up-regulation of intestinal vascular endothelial growth factor by Afa/Dr diffusely adhering Escherichia coli.

Authors:  Gaëlle Cane; Vanessa Liévin-Le Moal; Gilles Pagès; Alain L Servin; Paul Hofman; Valérie Vouret-Craviari
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

10.  A zebrafish model of inflammatory lymphangiogenesis.

Authors:  Kazuhide S Okuda; June Pauline Misa; Stefan H Oehlers; Christopher J Hall; Felix Ellett; Sultan Alasmari; Graham J Lieschke; Kathryn E Crosier; Philip S Crosier; Jonathan W Astin
Journal:  Biol Open       Date:  2015-09-14       Impact factor: 2.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.